Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...

BELLEVUE, Wash., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Truveta announced today that Truveta Data, the most complete, timely, and clean electronic health record (EHR) data, now includes more than 120 ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...